Bio-Rad Laboratories, Inc.（BIO）資訊與事件BIOBio-Rad Laboratories, Inc.

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

Biodesix (BDSX) announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease - or MRD - solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tumor DNA - ctDNA -, the tumor DNA that a cancer sheds into the blood, to assess whether disease remains or is returning after treatment. The tumor-informed solution is the result of a multi-year collaboration with Bio-Rad Laboratories (BIO). The tumor-naive solution is a newly launched program with Thermo Fisher Scientific (TMO) that extends a collaboration for companion diagnostic validation and other development work. Both approaches will be validated by Biodesix in collaboration with key investigators at Memorial Sloan Kettering Cancer Center or MSK, and are designed to run on partner platforms already installed in laboratories around the world. Tumor-informed testing is generally the most sensitive option when tumor tissue is available, and tumor-naive testing extends monitoring to patients whose tissue is unavailable or insufficient. Biodesix is advancing both, drawing on its proprietary Diagnostic Cortex bioinformatics platform. The two programs build on MRD data that Biodesix and its collaborators have presented at scientific meetings over the past two years.

Bio-Rad Implements Restructuring Plan Estimated Costs Up to $90 Million

According to a regulatory filing, on July 31, 2026, Bio-Rad Laboratories initiated a strategy-driven restructuring plan as part of our ongoing program to improve operating performance and strengthen the Company's competitive position. "The restructuring plan impacts our operations and functions throughout the world and includes the elimination of certain positions, the consolidation of certain functions, and the closure of various facilities," the company said. "We estimate that we will incur total pre-tax charges of approximately $80 to $90 million, which we anticipate will consist primarily of one-time termination benefits, including cash severance payments, healthcare benefits, and related transition assistance. The estimates for headcount reduction, timing and charges in certain areas of the international business are subject to completion of applicable local employee consultative processes. The restructuring plan is expected to be substantially completed by the end of fiscal year 2027."

Bio-Rad Reports Q2 Revenue of $651M, Beating Expectations

Reports Q2 revenue $651M, consenesus $623.99M. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating cash flow, and repurchased approximately $32 million of shares. We are reaffirming our full-year outlook, and remain focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation."